High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study

European Journal of Neurology

Volumn 22, Issue 4, 2015, Pages 672-e41

  Dobloug, G C ^a   Antal, E A ^b   Sveberg, L ^b   Garen, T ^a   Bitter, H ^c   Stjarne J ^d   Grovle L ^e   Gran, J T ^a   Molberg, O ^a,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Cancer and Surgery Clinic OUH   (Norway)

^c Sørlandet Hospital   (Norway)

^d Betanien Hospital   (Norway)

^e Sykehuset Ostfold   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

Epidemiology; European Neuro Muscular Centre Criteria; Idiopathic inflammatory myopathy; Sporadic inclusion body myositis

Indexed keywords

AUTOANTIBODY;

AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CASE FINDING; COHORT ANALYSIS; COMORBIDITY; DISEASE COURSE; DYSPHAGIA; ELECTRON MICROSCOPY; FEMALE; FOLLOW UP; GENDER BIAS; HUMAN; HUMAN TISSUE; ICD-10; INCLUSION BODY MYOSITIS; INFLAMMATORY INFILTRATE; ISCHEMIC HEART DISEASE; MALE; MEDICAL RECORD REVIEW; MORTALITY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; NORWAY; PATIENT CODING; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; RESEARCH DIAGNOSTIC CRITERIA; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SEX RATIO; SJOEGREN SYNDROME; UPREGULATION; DELAYED DIAGNOSIS; MIDDLE AGED; MYOSITIS, INCLUSION BODY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DELAYED DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; NORWAY; PREVALENCE;

EID: 84924455899     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12627     Document Type: Article

References (35)

1. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971; 25: 240-248.
2. Adams RD, Kakulas BA, Samaha FA. A myopathy with cellular inclusions. Trans Am Neurol Assoc 1965; 90: 213-216.
3. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158: 1453-1455.
4. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-1498.
5. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80: 1186-1193.
6. Finch CE. A perspective on sporadic inclusion-body myositis: the role of aging and inflammatory processes. Neurology 2006; 66(2 Suppl 1): S1-S6.
7. Uruha A, Nishino I. [Pathogenesis of inclusion body myositis: autoimmune or degenerative disease?]. Brain Nerve 2013; 65: 1291-1298.
8. Roos PM, Vesterberg O, Nordberg M. Inclusion body myositis in Alzheimer's disease. Acta Neurol Scand 2011; 124: 215-217.
9. Askanas V, Engel WK. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008; 116: 583-595.
10. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134(Pt 11): 3176-3184.
11. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134(Pt 11): 3167-3175.
12. Mulcahy KP, Langdon PC, Mastaglia F. Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence. Dysphagia 2012; 27: 64-69.
13. Cox FM, Verschuuren JJ, Verbist BM, et al. Detecting dysphagia in inclusion body myositis. J Neurol 2009; 256: 2009-2013.
14. Hohlfeld R. Update on sporadic inclusion body myositis. Brain 2011; 134(Pt 11): 3141-3145.
15. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-631.
16. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-713.
17. Verschuuren JJBU, Van Engelen BGM, et al. Inclusion body myositis. London: Royal Society of Medicine Press; 1997.
18. Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010; 20: 414-421.
19. Rose MR. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013; 23: 1044-1055.
20. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55: 1385-1387.
21. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000; 23: 970-972.
22. Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15: 1350-1353.
23. Tan JA, Roberts-Thomson PJ, Blumbergs P, et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 2013; 16: 331-338.
24. Nakanishi H, Koike H, Matsuo K, et al. Demographic features of Japanese patients with sporadic inclusion body myositis: a single-center referral experience. Intern Med 2013; 52: 333-337.
25. Suzuki N, Aoki M, Mori-Yoshimura M, et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 2012; 259: 554-556.
26. Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta Myol 2011; 30: 34-36.
27. Dobloug C, Garen T, Molberg O, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-205127. [Epub ahead of print].
28. Weitoft T. Occurrence of polymyositis in the county of Gavleborg, Sweden. Scand J Rheumatol 1997; 26: 104-106.
29. Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 2014; 34: 606-618.
30. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013; 84: 1240-1246.
31. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-424.
32. Mastaglia FL, Needham M, Scott A, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009; 19: 763-765.
33. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79: 1056-1060.
34. Rojana-udomsart A, Needham M, Luo YB, et al. The association of sporadic inclusion body myositis and Sjogren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 2011; 113: 559-563.
35. Nordang GB, Flam ST, Maehlen MT, Kvien TK, Viken MK, Lie BA. HLA-C alleles confer risk for anti-citrullinated peptide antibody-positive rheumatoid arthritis independent of HLA-DRB1 alleles. Rheumatology (Oxford) 2013; 52: 1973-1982.